MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may help High-Risk patients get Life-Saving stem cell transplants
Disease control Recruiting nowThis study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 17, 2026 05:20 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to standard therapy. Participants receive donor immune cells (NK cells) that are engineered to better target cancer, along with chemoth…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered immune cells take on relapsed blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to target and attack cancer cells. The…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Blood disorder drug luspatercept under Long-Term safety review
Disease control Recruiting nowThis study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were in earlier luspatercept trials. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare bone marrow cancer: targeted pill vs standard chemo
Disease control Recruiting nowThis study tests a daily pill (ivosidenib) against a standard chemotherapy (azacitidine) in adults with a bone marrow disorder called MDS that has a specific gene change (IDH1 mutation). About 48 people who have not had prior treatment with similar drugs will take part. The goal …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug cocktail may cut deadly transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests a new combination of drugs (bendamustine and cyclophosphamide) to prevent graft-versus-host disease and a dangerous immune reaction after stem cell transplants. It involves 60 adults with high-risk blood cancers who have a partially matched donor. The goal is to …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug duo targets tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called ICP-248 combined with a standard chemotherapy (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The main goals are to check safety, find the best dose, and see if the combo helps shrink the cancer. Abo…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New cord blood transplant method could boost survival in tough blood cancers
Disease control Recruiting nowThis study is testing an improved method for cord blood transplants in adults with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach helps patients live longer and have fewer side effects. About 54 participants will receive the tran…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC